|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for S100A13 |
 Gene summary |
| Basic gene Info. | Gene symbol | S100A13 |
| Gene name | S100 calcium binding protein A13 | |
| Synonyms | - | |
| Cytomap | UCSC genome browser: 1q21 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001024210.1, NM_001024211.1,NM_001024212.1,NM_001024213.1,NM_005979.2, | |
| Description | S100 calcium-binding protein A13protein S100-A13 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 601989 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000189171 | ||
| HPRD : 03586 | ||
| Protein | UniProt: Q99584 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_S100A13 | |
| BioGPS: 6284 | ||
| Pathway | NCI Pathway Interaction Database: S100A13 | |
| KEGG: S100A13 | ||
| REACTOME: S100A13 | ||
| Pathway Commons: S100A13 | ||
| Context | iHOP: S100A13 | |
| ligand binding site mutation search in PubMed: S100A13 | ||
| UCL Cancer Institute: S100A13 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0043123 | positive regulation of I-kappaB kinase/NF-kappaB signaling | 15033494 | GO:0050703 | interleukin-1 alpha secretion | 12746488 |
| Top |
| Ligand binding site mutations for S100A13 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | R29 | R29Q | COAD | 1 | S69 | S69W | LUAD | 1 | R29 | R29Q | STAD | 1 | E37 | E37K | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for S100A13 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | S69 | S69W | 0.26315038 | R29 | R29Q | -1.4031781 | E37 | E37K | -0.90205954 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for S100A13 from PDB |
| Top |
| Differential gene expression and gene-gene network for S100A13 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for S100A13 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for S100A13 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Approved | DB00768 | Olopatadine | Small molecule |  |
| Approved|investigational | DB01025 | Amlexanox | Small molecule |  |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of S100A13 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | CA | CALCIUM(2+) | 1yut | A | R29 E37 | CA | CALCIUM(2+) | 1yut | B | R29 E37 | CA | CALCIUM(2+) | 1yuu | A | R29 E37 | CA | CALCIUM(2+) | 1yuu | B | R29 E37 | CA | CALCIUM(2+) | 2egd | A | R29 E37 | CA | CALCIUM(2+) | 2egd | B | R29 E37 | CA | CALCIUM(2+) | 2h2k | A | R29 E37 | CA | CALCIUM(2+) | 2h2k | B | R29 E37 | CA | CALCIUM(2+) | 1yut | B | S69 |
| Top |
| Conservation information for LBS of S100A13 |
| Multiple alignments for Q99584 in multiple species |
| LBS | AA sequence | # species | Species |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |